The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Tissue-specific Expression of βKlotho and Fibroblast Growth Factor (FGF) Receptor Isoforms Determines Metabolic Activity of FGF19 and FGF21
Open accessAbstract
The fibroblast growth factor (FGF) 19 subfamily of ligands, FGF19, FGF21, and FGF23, function as hormones that regulate bile acid, fatty acid, glucose, and phosphate metabolism in target organs through activating FGF receptors (FGFR1-4). We demonstrated that Klotho and betaKlotho, homologous single-pass transmembrane proteins that bind to FGFRs, are required for metabolic activity of FGF23 and FGF21, respectively. Here we show that, like FGF21, FGF19 also requires betaKlotho. Both FGF19 and FGF21 can signal through FGFR1-3 bound by betaKlotho and increase glucose uptake in adipocytes expressing FGFR1. Additionally, both FGF19 and FGF21 bind to the betaKlotho-FGFR4 complex; however, only FGF19 signals efficiently through FGFR4. Accordingly, FGF19, but not FGF21, activates FGF signaling in hepatocytes that primarily express FGFR4 and reduces transcription of CYP7A1 that encodes the rate-limiting enzyme for bile acid synthesis. We conclude that the expression of betaKlotho, in combination with particular FGFR isoforms, determines the tissue-specific metabolic activities of FGF19 and FGF21.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“loss of KLB abolishes all effects of FGF21 in vitro and in vivo46,53–56.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [46]
In the citing paper
“FGF21 binding promotes the formation of a dimeric FGFR1c–KLB signalling complex, which activates the intracellular tyrosine kinase domains of FGFR1c and propagates signalling through phosphorylation by the kinase ERK46,53,58,59”
From Metabolic messengers: FGF21 (2021) · cites this paper as [46]
In the citing paper
“FGF21 elicits its biological effects by binding and activating a receptor complex composed of the co-receptor KLB and a traditional FGF receptor, fibroblast growth factor receptor 1c (FGFR1c)46,47.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [46]
In the citing paper
“Interestingly, both FGF21 and another endocrine FGF, FGF15/19, share a requirement for KLB for signaling46,54, but what cross-talk, if any, exists between these signalling pathways in both physiological and pharmacological settings is unclear.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [46]
In the citing paper
“FGF21 signals to a receptor complex comprised of FGF receptor 1c (FGFR1c) and its co-receptor β-klotho (KLB) [[143], [144], [145], [146]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [143]
In the citing paper
“Importantly, since FGF receptors are ubiquitously expressed, endocrine FGFs require a coreceptor to provide signaling specificity, which for FGF21 and FGF19 is the coreceptor β-klotho (71, 99, 140).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [71]
In the citing paper
“FGF21 functions in target tissues that express the traditional FGF receptor FGFR1c and the obligate coreceptor β-klotho (2, 27, 71, 99, 124, 140).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Self-citationFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Suppression of Aging in Mice by the Hormone Klotho
Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., McGuinness, O. P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., et al. (2005) · Science · doi:10.1126/science.1112766 · Cited by 1,935
Self-citationReceptor Specificity of the Fibroblast Growth Factor Family
Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Self-citationKlotho converts canonical FGF receptor into a specific receptor for FGF23
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., & Yamashita, T. (2006) · Nature · doi:10.1038/nature05315 · Cited by 1,865
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Self-citationShimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., & Yamashita, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19081 · Cited by 1,503
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K., Evans, W. E., O'Riordan, J., Speer, M., Econs, M., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,467
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 748
Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis
Wu, X., & Li, Y. (2009) · Aging · doi:10.18632/aging.100108 · Cited by 30
Sun, M. Y., Yoo, E., Green, B. J., Altamentova, S. M., Kilkenny, D. M., & Rocheleau, J. V. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.10.028 · Cited by 31
Fibroblast growth factor 21 and bone homeostasis
Tang, Y., & Zhang, M. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.07.002 · Cited by 31
Fibroblast growth factor 21 as a potential master regulator in metabolic disorders
Velingkar, A., Vuree, S., Prabhakar, P. K., Kalashikam, R. R., Banerjee, A., & Kondeti, S. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00244.2022 · Cited by 32
Role of fibroblast growth factors in organ regeneration and repair
Agha, E. E., Kosanovic, D., SCHERMULY, R. T., & Bellusci, S. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.009 · Cited by 33
Montford, J. R., Chonchol, M., Cheung, A. K., Kaufman, J. S., Greene, T., Roberts, W. L., Smits, G., Kendrick, J., & and the HOST Investigators (2013) · American Journal of Nephrology · doi:10.1159/000346941 · Cited by 31
FGF21 as a Therapeutic Reagent
Zhao, Y., Dunbar, J. D., & Kharitonenkov, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0887-1_14 · Cited by 30
The role of FGF21 in type 1 diabetes and its complications
Zhang, J., Weng, W., Wang, K., Lu, X., Cai, L., & Sun, J. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25026 · Cited by 30
Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases
Zhao, L., Niu, J., Lin, H., Zhao, J., Liu, Y., Song, Z., Xiang, C., Wang, X., Yang, Y., Li, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.052 · Cited by 30
Self-citationAhuja, P., Bi, X., Ng, C. F., Tse, M. C. L., Hang, M., Pang, B. P. S., Iu, E. C. Y., Chan, W. S., Ooi, X. C., Sun, A., et al. (2022) · Hepatology · doi:10.1002/hep.32501 · Cited by 30
FGF21 signalling pathway and metabolic traits – genetic association analysis
Kaess, B. M., Barnes, T. A., Stark, K. J., Charchar, F. J., Waterworth, D. M., Song, K. S., Wang, W. Y. S., Vollenweider, P., Waeber, G., Mooser, V., et al. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.130 · Cited by 30
Yang, M., Dong, J., Liu, H., Li, L., & Yang, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026359 · Cited by 30
Hu, L., & CONG, L.-X. (2015) · Oncology Reports · doi:10.3892/or.2015.4212 · Cited by 30
Curtailing FGF19’s mitogenicity by suppressing its receptor dimerization ability
Niu, J., Zhao, J., Wu, J., Qiao, G., Gu, J., Zhou, C., Li, Q., Lei, Y., Wang, D., Lin, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010984117 · Cited by 30
Self-citationJackson, T. C., Kotermanski, S. E., & Kochanek, P. M. (2018) · Developmental Neuroscience · doi:10.1159/000493637 · Cited by 28
Wang, R., Wang, F., Lu, S., Gao, B., Kan, Y., Yuan, T., Xu, Y., Yuan, C., Guo, D., Fu, W., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.04.006 · Cited by 28
Nelson, B. T., Ding, X., Bonéy-Montoya, J., Gerard, R. D., Kliewer, S. A., & Andrews, M. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053574 · Cited by 28
Self-citationFjeldborg, K., Pedersen, S. B., Møller, H. J., & Richelsen, B. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.03.033 · Cited by 28
Dianat‐Moghadam, H., & Teimoori‐Toolabi, L. (2019) · Current Drug Targets · doi:10.2174/1389450120666190112145409 · Cited by 28
QTL mapping for orange shell color and sex in the Pacific oyster (Crassostrea gigas)
Han, Z., Li, Q., Xu, C., Liu, S., Yu, H., & Kong, L. (2020) · Aquaculture · doi:10.1016/j.aquaculture.2020.735781 · Cited by 28
Moure, R., Cairó, M., Morón‐Ros, S., Quesada‐López, T., Campderrós, L., Cereijo, R., Hernáez, Á., Villarroya, F., & Giralt, M. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00270.2020 · Cited by 28
Wang, H., Yang, J., Zhang, K., Liu, J., Li, Y., Su, W., & Song, N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.650388 · Cited by 29
Kong, Y., Zhao, C., Tan, P., Liu, S., Huang, Y., Zeng, F., Ma, P., Guo, Y., Zhao, B., & Wang, J. (2022) · Animals · doi:10.3390/ani12070939 · Cited by 28
Adipokines: Deciphering the cardiovascular signature of adipose tissue
Galley, J. C., Singh, S., Awata, W. M. C., Alves, J. V., & Bruder-Nascimento, T. B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115324 · Cited by 32
Adapting to the cold: A role for endogenous fibroblast growth factor 21 in thermoregulation?
Klein Hazebroek, M., & Keipert, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00389 · Cited by 27
Current, emerging, and potential therapies for non-alcoholic steatohepatitis
Yang, Z. L., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152042 · Cited by 26
FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model
Uonaga, T., Toyoda, K., Okitsu, T., Zhuang, X., Yamane, S., Üemoto, S., & Inagaki, N. (2010) · Islets · doi:10.4161/isl.2.4.12402 · Cited by 27
Unliganded Fibroblast Growth Factor Receptor 1 Forms Density-independent Dimers
Comps‐Agrar, L., Dunshee, D. R., Eaton, D., & Sonoda, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.681395 · Cited by 27
Hatch, N. E., Li, Y., & Franceschi, R. T. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081213 · Cited by 27
Tarkkonen, K. M., Nilsson, E. M., Kähkönen, T. E., Dey, J. H., Heikkilä, J., Tuomela, J. M., Liu, Q., Hynes, N. E., & Härkönen, P. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049970 · Cited by 26
Targeting FGFR in Squamous Cell Carcinoma of the Lung
Hashemi‐Sadraei, N., & Hanna, N. H. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0513-6 · Cited by 26
Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism
Tassi, E., Garman, K. A., Schmidt, M. O., Ma, X., Kabbara, K. W., Üren, A., Tomita, Y. A., Goetz, R. M., Mohammadi, M., Wilcox, C. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34238-5 · Cited by 28
Self-citationLiu, Q., Wang, S., Wei, M., Huang, X., Cheng, Y., Shao, Y., Xia, P., Zhong, M., Liu, S., Zhang, G., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00566 · Cited by 27
Maresin 1 Regulates Hepatic FGF21 in Diet‐Induced Obese Mice and in Cultured Hepatocytes
Martínez‐Fernández, L., González‐Muniesa, P., Sáinź, N., Laiglesia, L. M., Escoté, X., Martínez, J. A., & Moreno-Aliaga, M. J. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900358 · Cited by 26
α-Klotho Expression in Mouse Tissues Following Acute Exhaustive Exercise
Rao, Z., Zheng, L., Hu, H., Feng, Y., & Shi, R. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01498 · Cited by 26
FGF21 Mimics a Fasting-Induced Metabolic State and Increases Appetite in Zebrafish
Blanco, A. M., Bertucci, J. I., & Unniappan, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-63726-w · Cited by 26
KLB dysregulation mediates disrupted muscle development in intrauterine growth restriction
Cortes‐Araya, Y., Stenhouse, C., Salavati, M., Dan‐Jumbo, S. O., Ho, W., Ashworth, C. J., Clark, E., Esteves, C. L., & Donadeu, F. X. (2022) · The Journal of Physiology · doi:10.1113/jp281647 · Cited by 26
Hu, Y., Xu, J., Shi, S. J., Zhou, X., Wang, L., Huang, L., Gao, L., Pang, W., Yang, G., & Chu, G. (2022) · Theriogenology · doi:10.1016/j.theriogenology.2022.09.020 · Cited by 26
Jeon, J. Y., Choi, S., Ha, E. S., Kim, T. H., Jung, J. G., Han, S. J., Kim, H. J., Kim, D. J., KANG, Y. Y., & Lee, K. W. (2016) · Endocrine · doi:10.1007/s12020-015-0845-x · Cited by 26
Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms
Heinle, J. W., DiJoseph, K., Sabag, A., Oh, S., Kimball, S. R., Keating, S., & Stine, J. G. (2023) · Nutrients · doi:10.3390/nu15112452 · Cited by 26
β-Klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice
Somm, E., Henry, H., Bruce, S. J., Bonnet, N., Montandon, S. A., Niederländer, N. J., Messina, A., Aeby, S., Rosikiewicz, M., Fajas, L., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00182.2018 · Cited by 28
Góralska, J., Raźny, U., Polus, A., Dziewońska, A., Gruca, A., Zdzienicka, A., Dembinska-Kiec, A., Solnica, B., Micek, A., Kapusta, M., et al. (2020) · Nutrients · doi:10.3390/nu12020476 · Cited by 26
Fibroblast Growth Factor 21 Facilitates the Homeostatic Control of Feeding Behavior
Wu, C.-T., CHAFFIN, A. T. B., & Ryan, K. K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030580 · Cited by 24
Yanucil, C., Kentrup, D., Li, X., Grabner, A., Schramm, K. J., Martinez, E. C., Li, J., Campos, I. D., Czaya, B. A., Heitman, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11033-x · Cited by 25
FGF21 suppresses hepatic glucose production through the activation of atypical protein kinase Cι/λ
Kong, L.-J., Feng, W., Wright, M., Chen, Y., Dallas-Yang, Q., Zhou, Y., & Berger, J. P. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.065 · Cited by 25
Miyaoka, Y., Tanaka, M., Imamura, T., Takada, S., & Miyajima, A. (2009) · Development · doi:10.1242/dev.041574 · Cited by 27
Nagai, N., Habuchi, H., Sugaya, N., Nakamura, M., Imamura, T., Watanabe, H., & Kimata, K. (2013) · Glycobiology · doi:10.1093/glycob/cwt037 · Cited by 25
Fibroblast Growth Factor Family in the Progression of Prostate Cancer
Teishima, J., Hayashi, T., Nagamatsu, H., Shoji, K., Shikuma, H., Yamanaka, R., Sekino, Y., Goto, K., Inoue, S., & Matsubara, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020183 · Cited by 29
The cell adhesion molecule L1 regulates the expression of FGF21 and enhances neurite outgrowth
Huang, X., Hu, J., Li, Y., Yang, Z. Z., Zhu, H., Zhou, L., Ma, K., Schachner, M., Xiao, Z., & Li, Y. (2013) · Brain Research · doi:10.1016/j.brainres.2013.07.043 · Cited by 24
Endocrine Fibroblast Growth Factors in Relation to Stress Signaling
Shimizu, M., & Sato, R. (2022) · Cells · doi:10.3390/cells11030505 · Cited by 25
Role of liver FGF21-KLB signaling in ketogenic diet-induced amelioration of hepatic steatosis
Guo, W., Cao, H., Shen, Y., Li, W., Wang, W. J., Cheng, L., Cai, M., & Xu, F. L. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00277-3 · Cited by 24
Claycombe, K., Vomhof‐DeKrey, E. E., Garcia, R. A. G., Johnson, W. T., Uthus, E. O., & Roemmich, J. N. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.01.008 · Cited by 24
MicroRNA-34a and Impaired FGF19/21 Signaling in Obesity
Fu, T., & Kemper, J. K. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.02.002 · Cited by 24
Therapeutic utilities of fibroblast growth factor 19
Wu, X., & Li, Y. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.624514 · Cited by 23
Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease
Rysz, J., Gluba-Brzózka, A., Mikhailidis, D. P., & Banach, M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1006357 · Cited by 23
Lin, Z., Hsu, C., Jeng, Y., Hu, F., Pan, H., Wu, Y., Hsu, H., & Cheng, A. (2019) · Liver International · doi:10.1111/liv.14055 · Cited by 23
Dong, K., Li, H., Zhang, M., Jiang, S., Chen, S., Zhou, J., Dai, Z., Fang, Q., & Jia, W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.104 · Cited by 23
Metabolic Syndrome in Pediatrics
Kursawe, R., & Santoro, N. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00004-8 · Cited by 23
Farnesoid X receptor as a regulator of fuel consumption and mitochondrial function
Han, C. Y., Kim, T. H., Koo, J. H., & Kim, S. G. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0812-y · Cited by 23
Hansen, A. M. K., Vienberg, S. G., Lykkegaard, K., Zhao, X., Tingqing, G., Han, D., Zhang, X., Thøgersen, H., Sass‐Ørum, K., Tagmose, T. M., et al. (2018) · Biochemical Journal · doi:10.1042/bcj20180555 · Cited by 23
Kanasaki, K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13219 · Cited by 23
Yamamoto, S., Koyama, D., Igarashi, R., Maki, T., Mizuno, H., Furukawa, Y., & Kuro‐o, M. (2020) · Internal Medicine · doi:10.2169/internalmedicine.3597-19 · Cited by 23
Self-citationCui, X., Sun, Q., & Wang, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1510322 · Cited by 24
Long-Term Dietary Taurine Lowers Plasma Levels of Cholesterol and Bile Acids
Tagawa, R., Kobayashi, M., Sakurai, M., Yoshida, M., Kaneko, H., Mizunoe, Y., Nozaki, Y., Okita, N., Sudo, Y., & Higami, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031793 · Cited by 22
Fibroblast growth factor 21: A “rheostat” for metabolic regulation?
She, Q.-Y., Bao, J., Wang, H.-Z., Liang, H., Huang, W., Wu, J., Zhong, Y.-W., Ling, H., Li, A., & Qin, S.-L. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155166 · Cited by 22
FGF19 Exhibits Neuroprotective Effects on Adult Mammalian Photoreceptors In Vitro
Siffroi‐Fernandez, S., Felder‐Schmittbuhl, M., Khanna, H., Swaroop, A., & Hicks, D. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1272 · Cited by 22
Gallego-Escuredo, J. M., Domingo, P., Gutiérrez, M. D. M., Mateo, G. M., Cabeza, M. C., Fontanet, À., Vidal, F., Domingo, J. C., Giralt, M., & Villarroya, F. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318271c2c7 · Cited by 22
FGF19 functions as autocrine growth factor for hepatoblastoma
Elzi, D. J., Song, M., Blackman, B., Weintraub, S. T., Lopez-Terrada, D. H., Chen, Y., Tomlinson, G. E., & Shiio, Y. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.101 · Cited by 22
Circulating Fibroblast Growth Factor 19 in Portal and Systemic Blood
Johansson, H., Mörk, L.-M., Li, M., Lövgren‐Sandblom, A., Björkhem, I., Höijer, J., Ericzon, B., Jorns, C., Gilg, S., Sparrelid, E., et al. (2017) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2017.07.001 · Cited by 22
Wang, D., Xu, S., Ding, W., Zhu, C., Deng, S., Qiu, X., & Wang, Z. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12859 · Cited by 21
The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism
Cariello, M., Piglionica, M., Gadaleta, R. M., & Moschetta, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_235 · Cited by 22
Lee, C., Su, S.-Y., Sittampalam, K., Chen, P. C.-H., Petersson, F., Kao, Y., Carpenter, T. O., Hsieh, T., Konishi, E., Tsai, J.-W., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0416-4 · Cited by 22
Supplementary Materials and Methods
Groenendijk, F. H., Zwart, W. T., Floore, A. N., Akbari, S., & Bernards, R. (2013) · Cited by 22
The role of FGF19 in metabolic regulation: insights from preclinical models to clinical trials
de Carvalho, M. B., Jorge, G. M. C. P., Zanardo, L. W., Hamada, L. M., Izabel, L. D. S., Santoro, S., & Magdalon, J. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00156.2024 · Cited by 23
Bile Secretion and the Enterohepatic Circulation
Dawson, P. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00064-0 · Cited by 23
Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities
Li, J., Duan, H., Liu, Y., Wang, L., & Zhou, X. W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071445 · Cited by 23
Hepatic FGF21 production is increased in late pregnancy in the mouse
Cui, Y., Giesy, S. L., Hassan, M., Davis, K., Zhao, S., & Boisclair, Y. R. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00554.2013 · Cited by 21
Making Way for Suppressing the FGF19/FGFR4 Axis in Cancer
Prieto‐Domínguez, N., Shull, A. Y., & Teng, Y. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0099 · Cited by 21
Lewis, J. E., Monnier, C., Marshall, H. J., Fowler, M. J., Green, R., Cooper, S., Chiotellis, A., Luckett, J., Perkins, A. C., Coşkun, T., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.009 · Cited by 25
Stenhouse, C., Halloran, K. M., Newton, M. G., Gaddy, D., Suva, L. J., & Bazer, F. W. (2021) · Biology of Reproduction · doi:10.1093/biolre/ioab028 · Cited by 21
Wu, X., & Li, Y. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0887-1_13 · Cited by 21
A Novel Approach to Improve the Function of FGF21
Smith, R. W., Duguay, A. N., Weiszmann, J., Stanislaus, S., Belouski, E., Cai, L., Yie, J., Xu, J., Gupte, J., Wu, X., et al. (2013) · BioDrugs · doi:10.1007/s40259-013-0013-x · Cited by 20
Ippagunta, S. M., Kharitonenkov, A., Adams, A. C., & Hillgartner, F. B. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy022 · Cited by 21
Current understanding and controversies on the clinical implications of fibroblast growth factor 21
Badakhshi, Y., & Jin, T. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1864278 · Cited by 20
Marchelek‐Myśliwiec, M., Dziedziejko, V., Nowosiad-Magda, M., Dołęgowska, K., Dołęgowska, B., Pawlik, A., Safranow, K., Wiśniewska, M., Stępniewska, J., Domański, M., et al. (2019) · Kidney & Blood Pressure Research · doi:10.1159/000502647 · Cited by 20
Nakano, T., Shiizaki, K., Miura, Y., Matsui, M., Kosaki, K., Mori, S., Yamagata, K., Maeda, S., Kishi, T., Usui, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55643-4 · Cited by 20
Self-citationReceptor Antibodies as Novel Therapeutics for Diabetes
Ussar, S., Vienberg, S. G., & Kahn, C. R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003447 · Cited by 19
Clinical significance of α- and β-Klotho in urothelial carcinoma of the bladder
Hori, S., Miyake, M., Onishi, S., Tatsumi, Y., Morizawa, Y., Nakai, Y., Anai, S., Tanaka, N., & Fujimoto, K. (2016) · Oncology Reports · doi:10.3892/or.2016.5053 · Cited by 19
Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer
Karin, M., & Kim, J. Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100096 · Cited by 20
The FGFR D3 Domain Determines Receptor Selectivity For Fibroblast Growth Factor 21
Gupte, J., Li, Y., Wu, X., Weiszmann, J., Hecht, R. I., Lemon, B. D., Lindberg, R. A., Wang, Z., & Li, Y. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.003 · Cited by 18
Brooks, N. E., Hjortebjerg, R., Henry, B. E., List, E. O., Kopchick, J. J., & Berryman, D. E. (2016) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2016.08.003 · Cited by 18
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis
Ronca, V., Carbone, M., Bernuzzi, F., Malinverno, F., Mousa, H. S., Gershwin, M. E., & Invernizzi, P. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1391093 · Cited by 18
Ageing-related receptors resolved
Kuro‐o, M. (2018) · Nature · doi:10.1038/d41586-017-09032-4 · Cited by 18
Self-citationFibroblast growth factors 19 and 21 in acute liver damage
Shan, Z., Álvarez‐Sola, G., Uriarte, I., Arechederra, M., Fernández‐Barrena, M. G., Berasain, C., Ju, C., & Avila, M. A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.26 · Cited by 19
Krumm, C. S., Giesy, S. L., Caixeta, L. S., Perfield, J. W., Sauerwein, H., Moore, B. L., & Boisclair, Y. R. (2019) · Journal of Dairy Science · doi:10.3168/jds.2019-16695 · Cited by 18
Bono, B. S. M., Ly, N. K. K., Miller, P. A., Williams-Ikhenoba, J. G., Dumiaty, Y., & Chee, M. J. S. (2022) · The Journal of Comparative Neurology · doi:10.1002/cne.25306 · Cited by 19
Laeger, T., Castaño-Martinez, T., Werno, M. W., Japtok, L., Baumeier, C., Jonas, W., Kleuser, B., & Schürmann, A. (2018) · Diabetologia · doi:10.1007/s00125-018-4595-1 · Cited by 17
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults
Ogawa, Y., Yoneda, M., Kobayashi, T., Honda, Y., Kessoku, T., Imajo, K., Saito, S., & Nakajima, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543403 · Cited by 18
Self-citationKlotho in Cancer: Potential Diagnostic and Prognostic Applications
Mota, J., Lima, A. M. M., Gomes, J. I. S., de Andrade, M. S., Brito, H. O., Silva, M. M. L., Faustino‐Rocha, A. I., Oliveira, P. A., Lopes, F. F., & da Costa, R. M. G. (2023) · Diagnostics · doi:10.3390/diagnostics13213357 · Cited by 24
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Chui, Z. S. W., Xue, Y., & Xu, A. (2024) · Medical Review · doi:10.1515/mr-2024-0007 · Cited by 21
Metadata
- Authors
- Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- New York University (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 282
- Issue
- 37
- Pages
- 26687-26695
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC2496965
- OpenAlex
- W2048411348
- Cited by
- 748
- References
- 35
- Citations by year
- 2026: 37 · 2025: 24 · 2024: 33 · 2023: 31 · 2022: 55 · 2021: 46 · 2020: 44 · 2019: 48 · 2018: 52 · 2017: 47 · 2016: 38 · 2015: 40 · 2014: 43 · 2013: 43 · 2012: 51
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Ellison Medical Foundation
- Welch Foundation
- Ted Nash Long Life Foundation
- Eisai
- National Institutes of Health (1r01ag015326-01, DK067158)
- National Institute on Aging (R01AG19712, R01AG025326, R01 AG 15326, R01AG019712)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-067158, R01DK067158)
- National Institute of Dental and Craniofacial Research (R01DE13686, R01DE013686)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- β-Klotho, Klotho, FGF19, FGF21, fibroblast growth factor 23, fibroblast growth factor receptor, FGFR4, FGFR1, tissue-specific signaling, bile acid metabolism, CYP7A1, hepatocytes, metabolic hormones
- MeSH terms
- Fibroblast Growth Factor-23, Klotho Proteins, Animals, Cholesterol 7-alpha-Hydroxylase, Fibroblast Growth Factors, Humans, Membrane Proteins, Organ Specificity, Phosphorylation, Signal Transduction, Adipocytes, Protein Isoforms, Hepatocytes, 3T3-L1 Cells, Extracellular Signal-Regulated MAP Kinases, Mice, Rats, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review